<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37422503</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>08</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Serum RGC-32 in children with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>11047</StartPage><MedlinePgn>11047</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11047</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-38092-y</ELocationID><Abstract><AbstractText>Childhood-onset systemic lupus erythematosus (SLE) can be more severe than adult patients. Early diagnosis and accurate evaluation of the disease are very important for the patients. Response gene to complement-32 (RGC-32) protein is the downstream regulator of C5b-9 complex which is the terminal pathway of complement activation. Complement system plays a very important role in the pathogenesis of SLE. RGC-32 in patients with SLE has not been reported yet. We aimed to examine the clinical value of RGC-32 in children with SLE. A total of 40 children with SLE and another 40 healthy children were enrolled for this study. Clinical data were obtained prospectively. Serum RGC-32 was determined by ELISA. We found that serum RGC-32 was significantly elevated in children with SLE than that in the healthy group. Serum RGC-32 was significantly higher in the children with moderately/severely active SLE than that in the children with no/mildly active SLE. Furthermore, serum RGC-32 level correlated positively with C-reactive protein, erythrocyte sedimentation rate and ferritin and correlated negatively with white blood cell counts and C3. RGC-32 may be involved in the pathogenesis of SLE. RGC-32 might become a good biomarker in the diagnosis and evaluation of SLE.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Bingxue</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Rheumatology and Immunology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Rheumatology and Immunology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Xiaoling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Rheumatology and Immunology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Wenyan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Rheumatology and Immunology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China. huangwy@shchildren.com.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Rheumatology and Immunology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China. haos@shchildren.com.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2018YQN003</GrantID><Agency>Shanghai Children's Hospital</Agency><Country/></Grant><Grant><GrantID>2020YGZM01</GrantID><Agency>Shanghai Children's Hospital</Agency><Country/></Grant><Grant><GrantID>YG2021QN118</GrantID><Agency>Shanghai Jiao Tong University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-36-7</RegistryNumber><NameOfSubstance UI="D003165">Complement System Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C115049">RGCC protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003165" MajorTopicYN="N">Complement System Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>9</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>8</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37422503</ArticleId><ArticleId IdType="pmc">PMC10329644</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-38092-y</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-38092-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An update on the management of childhood-onset systemic lupus erythematosus. Paediatr. Drugs. 2021;23:331&#x2013;347. doi: 10.1007/s40272-021-00457-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40272-021-00457-z</ArticleId><ArticleId IdType="pmc">PMC8270778</ArticleId><ArticleId IdType="pubmed">34244988</ArticleId></ArticleIdList></Reference><Reference><Citation>Barsalou J, Levy DM, Silverman ED. An update on childhood-onset systemic lupus erythematosus. Curr. Opin. Rheumatol. 2013;25:616&#x2013;622. doi: 10.1097/BOR.0b013e328363e868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0b013e328363e868</ArticleId><ArticleId IdType="pubmed">23836073</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal A, Srivastava P. Childhood onset systemic lupus erythematosus: How is it different from adult SLE? Int. J. Rheum. Dis. 2015;18:182&#x2013;191. doi: 10.1111/1756-185X.12419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.12419</ArticleId><ArticleId IdType="pubmed">24965742</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlaicu SI, Tatomir A, Anselmo F, Boodhoo D, Chira R, Rus V, et al. RGC-32 and diseases: The first 20 years. Immunol. Res. 2019;67:267&#x2013;279. doi: 10.1007/s12026-019-09080-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-019-09080-0</ArticleId><ArticleId IdType="pubmed">31250246</ArticleId></ArticleIdList></Reference><Reference><Citation>Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res. 2002;4:S279&#x2013;S293. doi: 10.1186/ar586.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar586</ArticleId><ArticleId IdType="pmc">PMC3240161</ArticleId><ArticleId IdType="pubmed">12110148</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. (Hoboken). 2012;64:797&#x2013;808. doi: 10.1002/acr.21664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21664</ArticleId><ArticleId IdType="pmc">PMC3437757</ArticleId><ArticleId IdType="pubmed">22556106</ArticleId></ArticleIdList></Reference><Reference><Citation>Cody EM, Brunner HI. Biomarkers in childhood-onset systemic lupus erythematosus. Rheum. Dis. Clin. N. Am. 2022;48:271&#x2013;285. doi: 10.1016/j.rdc.2021.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2021.09.003</ArticleId><ArticleId IdType="pubmed">34798952</ArticleId></ArticleIdList></Reference><Reference><Citation>Badea TC, Niculescu FI, Soane L, Shin ML, Rus H. Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. J. Biol. Chem. 1998;273:26977&#x2013;26981. doi: 10.1074/jbc.273.41.26977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.41.26977</ArticleId><ArticleId IdType="pubmed">9756947</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegla CA, Cudrici CD, Nguyen V, Danoff J, Kruszewski AM, Boodhoo D, et al. RGC-32 is a novel regulator of the T-lymphocyte cell cycle. Exp. Mol. Pathol. 2015;98:328&#x2013;337. doi: 10.1016/j.yexmp.2015.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2015.03.011</ArticleId><ArticleId IdType="pmc">PMC5061555</ArticleId><ArticleId IdType="pubmed">25770350</ArticleId></ArticleIdList></Reference><Reference><Citation>Fosbrink M, Cudrici C, Tegla CA, Soloviova K, Ito T, Vlaicu S, et al. Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial Cells. Exp. Mol. Pathol. 2009;86:87&#x2013;94. doi: 10.1016/j.yexmp.2008.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexmp.2008.12.005</ArticleId><ArticleId IdType="pmc">PMC2699899</ArticleId><ArticleId IdType="pubmed">19162005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Jang J, Lee EH, Jung S, Roh JY, Jung YJ. Decreased expression of response gene to complement 32 in psoriasis and its association with reduced M2 macrophage polarization. J. Dermatol. 2019;46:166&#x2013;168. doi: 10.1111/1346-8138.14733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1346-8138.14733</ArticleId><ArticleId IdType="pubmed">30600542</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YJ, Chang WA, Wu LY, Hsu YL, Chen CS, Kuo PL. Systematic analysis of differential expression profile in rheumatoid arthritis chondrocytes using next-generation sequencing and bioinformatics approaches. Int. J. Med. Sci. 2018;15:1129&#x2013;1142. doi: 10.7150/ijms.27056.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.27056</ArticleId><ArticleId IdType="pmc">PMC6097257</ArticleId><ArticleId IdType="pubmed">30123050</ArticleId></ArticleIdList></Reference><Reference><Citation>Myriam M, Smol&#x105;g KI, Bj&#xf6;rk A, Gullstrand B, Okroj M, Leffler J, et al. Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus. Arthritis Res. Ther. 2017;19:266. doi: 10.1186/s13075-017-1470-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-017-1470-2</ArticleId><ArticleId IdType="pmc">PMC5717799</ArticleId><ArticleId IdType="pubmed">29208014</ArticleId></ArticleIdList></Reference><Reference><Citation>Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum. 2004;50:2048&#x2013;2065. doi: 10.1002/art.20345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20345</ArticleId><ArticleId IdType="pubmed">15248202</ArticleId></ArticleIdList></Reference><Reference><Citation>Porcel JM, Ordi J, Castrosalomo A, Vilardell M, Rodrigo MJ, Gene T, et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin. Immunol. Immunopathol. 1995;74:283&#x2013;288. doi: 10.1006/clin.1995.1040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/clin.1995.1040</ArticleId><ArticleId IdType="pubmed">7859418</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu YY, Nisihara RM, W&#xfc;rzner R, Kirschfink M, Messiasreason IJ. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients. Investig. Allergol. Clin. Immunol. 1998;8:239&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">9777539</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang WY, Li ZG, Rus H, Wang XY, Jose PA, Chen SY. RGC-32 mediates transforming growth factor-beta-induced epithelial-mesenchymal transition in human renal proximal tubular cells. J. Biol. Chem. 2009;284:9426&#x2013;9432. doi: 10.1074/jbc.M900039200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M900039200</ArticleId><ArticleId IdType="pmc">PMC2666595</ArticleId><ArticleId IdType="pubmed">19158077</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen YL, Liu HJ, Sun L, Niu XL, Kuang XY, Wang P, et al. Response gene to complement 32 regulates the G2/M phase checkpoint during renal tubular epithelial cell repair. Cell Mol. Biol. Lett. 2016;21:19. doi: 10.1186/s11658-016-0021-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s11658-016-0021-1</ArticleId><ArticleId IdType="pmc">PMC5415738</ArticleId><ArticleId IdType="pubmed">28536621</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu XL, Kuang XY, Zhang ZG, Liu XG, Zhao ZH, Zhang X, et al. Expression of response gene to complement 32 in renal tissue of children with IgA nephropathy and its significance. China J. Nehprol. 2011;27:479&#x2013;483.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>